Evidence map›Paper›PMID 34677667›Full record

ArticleArchivum immunologiae et therapiae experimentalis2021

Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients.

Katarzyna Bąbol-Pokora, Magdalena Wołowiec, Katarzyna Popko, Aleksandra Jaworowska, Yenan T Bryceson, Bianca Tesi, Jan-Inge Henter, Wojciech Młynarski, Wanda Badowska, Walentyna Balwierz and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 2 countries.

Katarzyna Bąbol-Pokora *Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Magdalena Wołowiec *Department of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091, Warsaw, Poland.
Katarzyna PopkoDepartment of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland.
Aleksandra JaworowskaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Yenan T BrycesonDepartment of Medicine, Centre for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Bianca TesiDepartment of Medicine, Centre for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Jan-Inge HenterDepartment of Medicine, Centre for Hematology and Regenerative Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Wojciech MłynarskiDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Lodz, Poland.
Wanda BadowskaDivision of Pediatric Hematology and Oncology, Children Hospital, Olsztyn, Poland.
Walentyna BalwierzDepartment of Pediatrics Oncology and Hematology, University Children's Hospital, Jagiellonian University Collegium Medicum, Krakow, Poland.
Katarzyna DrabkoDepartment of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical University of Lublin, Lublin, Poland.
Krzysztof KałwakDepartment of Pediatric Stem Cell Transplantation, Hematology and Oncology, Medical University, Wroclaw, Poland.
Lucyna Maciejka-KembłowskaDepartment of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
Anna PieczonkaDepartment of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
Grażyna Sobol-MilejskaDepartment of Pediatrics, Hematology and Oncology, Medical University of Silesia, Silesia, Poland.
Sylwia KołtanDepartment of Pediatrics, Hematology and Oncology, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland.
Iwona MalinowskaDepartment of Pediatrics, Hematology and Oncology, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091, Warsaw, Poland. iwona.malinowska@wum.edu.pl.ORCID http://orcid.org/0000-0003-0671-7849
Polish Pediatric Hematology, Oncology Society
Karolinska University Hospital · SEMedical University of Lodz · PLMedical University of Warsaw · PLGdańsk Medical University · PLJagiellonian University · PLMedical University of Lublin · PLMedical University of Silesia · PLNicolaus Copernicus University · PLPoznan University of Medical Sciences · PLUniversity of Computer Sciences and Economics in Olsztyn · PLWroclaw Medical University · PL

Funding

Narodowe Centrum Nauki NCN 0989/B/P01/2011/40
6 · The paper itself

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a clinical syndrome of life-threatening inflammation caused by an excessive, prolonged and ineffective immune response. An increasing number of HLH cases is recognized in Poland, but the genetic causes of familial HLH (FHL) have not been reported. We investigated the molecular genetics and associated outcomes of pediatric patients who met HLH criteria. We studied 54 patients with HLH, 36 of whom received genetic studies. Twenty-five patients were subjected to direct sequencing of the PRF1, UNC13D, STX11, XIAP and SH2D1A genes. Additionally, 11 patients were subjected to targeted next-generation sequencing. In our study group, 17 patients (31%) were diagnosed with primary HLH, with bi-allelic FHL variants identified in 13 (36%) patients whereas hemizygous changes were identified in 4 patients with X-linked lymphoproliferative diseases. In addition, one patient was diagnosed with X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia due to a hemizygous MAGT1 variant; another newborn was diagnosed with auto-inflammatory syndrome caused by MVK variants. The majority (65%) of FHL patients carried UNC13D pathogenic variants, whereas PRF1 variants occurred in two patients. Novel variants in UNC13D, PRF1 and XIAP were detected. Epstein-Barr virus was the most common trigger noted in 23 (65%) of the patients with secondary HLH. In three patients with secondary HLH, heterozygous variants of FHL genes were found. Overall survival for the entire study group was 74% with a median of 3.6 years of follow-up. Our results highlight the diversity of molecular causes of primary HLH in Poland.

Indexed as

Epstein-Barr Virus InfectionsLymphohistiocytosis, HemophagocyticChildHerpesvirus 4, HumanHumansInfant, NewbornMembrane ProteinsMolecular BiologyPerforinPolandMembrane ProteinsPerforinUNC13D protein, humanClinical courseGeneticsHemophagocytic lymphohistiocytosisNovel variants

Identifiers

PMID34677667
PMCPMC8536594
OpenAlexW3207355614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.